Blood samples were obtained from healthy donors who had not taken non-steroidal anti-inflammatory drugs during the 10 days before sampling, or from T2DM patients diagnosed according to the American Diabetes Association criteria41 . Patients with active infections or under chronic treatment with ASA were excluded. Patients received standard care by their treating physicians and were treated with metformin and statins at different doses. A routine examination was performed. Systolic and diastolic blood pressures were determined using a standardised protocol. Venous blood samples (20 mL) were obtained after a 12-h overnight fast. Fasting plasma glucose was determined by the glucose-oxidase method (GLU Glucose GOD-PAP, Roche Diagnostics, Mannheim, Germany) in a Hitachi 727 auto-analyser. Levels of triglycerides (TG) and high-density lipoprotein cholesterol (HDL-C) were determined in the serum by standard enzymatic methods using commercial kits (TG Triglycerides GPO-PAP and Phosphotungstate Precipitant, Roche Diagnostics, Mannheim, Germany) with a Hitachi 727 auto-analyser. HbA1c was measured by HPLC using a commercial kit (Roche Diagnostics, Mannheim, Germany). As a control group, eight healthy individuals of the same age and gender were also evaluated.
Glu glucose god pap
Manufactured by Roche
Sourced in Germany
The GLU Glucose GOD-PAP is a laboratory equipment product designed for the quantitative determination of glucose in biological fluids. It utilizes the glucose oxidase (GOD) and peroxidase (PAP) enzymatic method to measure glucose concentrations.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using glu glucose god pap
1
Metabolic Profiles in Type 2 Diabetes
2
Plasma glucose and insulin pharmacodynamics
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Plasma samples for measuring glucose and insulin were taken at the following time points after a single oral administration of HMS5552 on day 1: pre-dose (−0.5, −0.25, and 0 hours), 0.25, 0.5, 1, 2, 3, 4, 4.25, 4.5, 5, and 6 hours. Plasma glucose concentrations were determined by an enzymatic oxidation method (GLU Glucose GOD-PAP, Roche Diagnostics, Mannheim, Germany), while insulin was analyzed by radioimmunoassay (kit catalog number H1-14K, Merck Millipore, Billerica, MA, USA).
Plasma glucose levels were used to calculate the following PD parameters: maximum glucose change from baseline (%), mean glucose area under effect curve 0–4 hours (AUEC0–4), mean glucose AUEC0–4 change from baseline (%). Baseline values were obtained on day −1.
Plasma glucose levels were used to calculate the following PD parameters: maximum glucose change from baseline (%), mean glucose area under effect curve 0–4 hours (AUEC0–4), mean glucose AUEC0–4 change from baseline (%). Baseline values were obtained on day −1.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!